dihydroergotamine has been researched along with thromboxane b2 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Burkel, WE; Graham, LM; Lindblad, B; Stanley, JC; Wakefield, TW | 1 |
Bellou, A; Gerard, P; Gillois, P; Guéant, JL; Lambert, H; Longrois, D; Mallié, JP; Montémont, C; Sainte-Laudy, J; Vauthier, E | 1 |
2 other study(ies) available for dihydroergotamine and thromboxane b2
Article | Year |
---|---|
Lack of effect of dihydroergotamine on endothelial and smooth muscle cell proliferation and endothelial cell prostanoid production.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Cell Division; Dihydroergotamine; Dogs; Endothelium, Vascular; Muscle, Smooth, Vascular; Prostaglandins; Thromboxane B2 | 1988 |
Constitutive nitric oxide synthase inhibition combined with histamine and serotonin receptor blockade improves the initial ovalbumin-induced arterial hypotension but decreases the survival time in brown norway rats anaphylactic shock.
Topics: Anaphylaxis; Animals; Arteries; Cimetidine; Dihydroergotamine; Dinoprostone; Eicosanoids; Enzyme Inhibitors; Heart; Histamine; Hypotension; Leukotriene C4; Male; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Ovalbumin; Pressure; Rats; Rats, Inbred BN; Receptors, Serotonin; Serotonin; Thromboxane B2; Time Factors | 2003 |